Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: Relevance to prostate cancer and benign hyperplasia

Prostate

Volumn 69, Issue 3, 2009, Pages 283-292

  Zeng, Yu ^a,b   Kakehi, Yoshiyuki ^a   Nouh, Mohammed Ahmed Abdel Muneem ^a   Tsunemori, Hiroyuki ^a   Sugimoto, Mikio ^a   Wu, Xiu Xian ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autotaxin; Benign prostate hyerplasia; Cancer; Laser capture microdissection; LPA; Prostate

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; ANDROGEN; AUTOTAXIN; GLYCEROL KINASE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; MESSENGER RNA; RECEPTOR SUBUNIT; AGK PROTEIN, HUMAN; ENPP2 PROTEIN, HUMAN; INORGANIC PYROPHOSPHATASE; LECTIN; LYSOPHOSPHOLIPID; MULTIENZYME COMPLEX; PANCREATITIS ASSOCIATED PROTEIN; PANCREATITIS-ASSOCIATED PROTEIN; PHOSPHODIESTERASE I; PHOSPHOTRANSFERASE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CELL DEGENERATION; CELL MATURATION; CELL MEMBRANE PERMEABILITY; CELL MOTION; CELL STRAIN LNCAP; CLINICAL ARTICLE; ENZYME DEGRADATION; EPITHELIUM CELL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MALE; MOLECULE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; STEM CELL; STROMA; STROMA CELL; BLADDER TUMOR; GENETICS; METABOLISM; MICRODISSECTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; ANDROGENS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; LECTINS, C-TYPE; LYSOPHOSPHOLIPIDS; MALE; MICRODISSECTION; MIDDLE AGED; MULTIENZYME COMPLEXES; PHOSPHODIESTERASE I; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PYROPHOSPHATASES; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 60849120762     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20879     Document Type: Article

References (36)

1. Grayhack JT, Kozlowski JM. Benign prostatic hyperplasia. In: Gillenwater JY, Grayhack JT, Howards SS, Duckett JM, editors. Adult and pediatric urology, 3rd edition. St. Louis: Mosby; 1996. 1501 p.
2. Grayhack JT, Lee C, Brand W. The effect of testicular irradiation on established BPH in the dog: Evidence of a non-steroidal testicular factor for BPH maintenance. J Urol 1985;134(6):1276-1281.
3. Sutkowski DM, Kasjanski RZ, Sensibar JA, Ney KG, Lim DJ, Kozlowski JM, Lee C, Grayhack JT. Effect of spermatocele fluid on growth of human prostatic cells in culture. J Androl 1993; 14(4):233-239.
4. Juniewicz PE, Berry SJ, Coffey DS, Strandberg JD, Ewing LL. The requirement of the testis in establishing the sensitivity of the canine prostate to develop benign prostatic hyperplasia. J Urol 1994;152(3):996-1001.
5. Grayhack JT, Sensibar JA, Ilio KY, Kasjanski RZ, Kozlowski JM, Lee C. Synergistic action of steroids and spermatocele fluid on in vitro proliferation of prostate stroma. J Urol 1998;159(6):2202-2209.
6. Tigyi G, Parrill AL. Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 2003;42(6):498-526.
7. Tokumura A. A family of phospholipid autacoids: Occurrence, metabolism and bioactions. Prog Lipid Res 1995;34(2):151-184.
8. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3(8):582-591.
9. Yoshida K, Nishida W, Hayashi K, Ohkawa Y, Ogawa A, Aoki J, Arai H, Sobue K. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 2003;108(14):1746-1752.
10. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A. Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J Lipid Res 2002;43(12):2049-2055.
11. Wang J, Okamoto Y, Morishita J, Tsuboi K, Miyatake A, Ueda N. Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-beta-lactamase family. J Biol Chem 2006;281(18):12325-12335.
12. Tokumura A, Miyake M, Nishioka Y, Yamano S, Aono T, Fukuzawa K. Production of lysophosphatidic acids by lyso-phospholipase D in human follicular fluids of in vitro fertilization patients. Biol Reprod 1999;61(1):195-199.
13. Hama K, Bandoh K, Kakehi Y, Aoki J, Arai H. Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: Possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett 2002;523(1 -3):187-192.
14. Kue PF, Daaka Y. Essential role for G proteins in prostate cancer cell growth and signaling. J Urol 2000;164(6):2162-2167.
15. Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem 2004;279(20):20555-20558.
16. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, Suzuki H, Amano T, Kennedy G, Arai H, Aoki J, Chun J. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 2005;435(7038):104-108.
17. Raj GV, Barki-Harrington L, Kue PF, Daaka Y. Guanosine phosphate binding protein coupled receptors in prostate cancer: A review. J Urol 2002;167(3):1458-1463.
18. Raj GV, Sekula JA, Guo R, Madden JF, Daaka Y. Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB. Prostate 2004; 61(2):105-113.
19. Guo R, Kasbohm EA, Arora P, Sample CJ, Baban B, Sud N, Sivashanmugam P, Moniri NH, Daaka Y. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 2006;147(10):4883-4892.
20. Sivashanmugam P, Tang L, Daaka Y. Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells. J Biol Chem 2004;279(20):21154-21159.
21. Adolfsson PI, Ahlstrand C, Varenhorst E, Svensson SP. Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: Sildenafil and papaverin generate inhibition. Prostate 2002;51(1):50-58.
22. Sakamoto S, Yokoyama M, Zhang X, Prakash K, Nagao K, Hatanaka T, Getzenberg RH, Kakehi Y. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Endocrinology 2004;145(6):2929-2940.
23. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002;277(42):39436-39442.
24. Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 2005;169(5):801-811.
25. Lin MF, Garcia-Arenas R, Xia XZ, Biela B, Lin FF. The cellular level of prostatic acid phosphatase and the growth of human prostate carcinoma cells. Differentiation 1994;57(2):143-149.
26. Lin MF, Lee MS, Zhou XW, Andressen JC, Meng TC, Johansson SL, West WW, Taylor RJ, Anderson JR, Lin FF. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J Urol 2001; 166(5):1943-1950.
27. Tanaka M, Kishi Y, Takanezawa Y, Kakehi Y, Aoki J, Arai H. Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma. FEBS Lett 2004;571(1-3):197-204.
28. Takagi H, Shibutani M, Kato N, Fujita H, Lee KY, Takigami S, Mitsumori K, Hirose M. Microdissected region-specific gene expression analysis with methacarn-fixed, paraffin-embedded tissues by real-time RT-PCR. J Histochem Cytochem 2004;52(7):903-913.
29. Wu X, Kakehi Y, Zeng Y, Taoka R, Tsunemori H, Inui M. Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: Comparison with cytokeratin 20. J Urol 2005;174(6):2138-2142.
30. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002; 158(2):227-233.
31. Kitayama J, Shida D, Sako A, Hama K, Aoki J, Arai H, Nagawa H. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 2004;6(6):R640-R646.
32. Daaka Y. Mitogenic action of LPA in prostate. Biochim Biophys Acta 2002;1582(1-3):265-269.
33. Im DS, Heise CE, Harding MA, George SR, O'Dowd BF, Theodorescu D, Lynch KR. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol Pharmacol 2000;57(4):753-759.
34. Guo C, Luttrell LM, Price DT. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 2000; 163(3):1027-1032.
35. Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, Tsujimoto M, Arai H, Inoue K. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 1999;274(39):27776-27785.
36. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T, Arai H. Autotaxin is over-expressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidyl-choline to lysophosphatidic acid. J Biol Chem 2006;281(25): 17492-17500.